Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TAF11L3 encodes a protein structurally similar to TATA-box binding protein associated factor 11 (TAF11), both predicted to be components of the TFIID transcription factor complex that initiates RNA polymerase II-dependent transcription. TFIID is a large multiprotein complex, composed of TATA-box binding protein (TBP) and multiple TBP-associated factors (TAFs), that coordinates the assembly of the transcription preinitiation complex and mediates regulatory signals[2][3][5][1]. TAF11L3 is predicted, not confirmed, to contribute to general transcription initiation and to be expressed in the nucleus, with no direct evidence of clinical application or drug interactions. Its functional annotation is mainly based on paralogy and structural homology to TAF11, which directly interacts with TBP and other basal transcription factors in promoter recognition and stabilization of the preinitiation complex[3][1][5]. Overall, TAF11L3 remains a gene with limited empirical data regarding disease, drug interaction, or specific therapeutic roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TATA-box binding protein associated factor 11 like 3 (TAF11L3).